- Fellowship - UT Southwestern Medical Center (2005-2008), Cardiology
- Residency - University of Pennsylvania Health System (2002-2005), Internal Medicine
- Medical School - Duke University School of Medicine (1998-2002)
Anand Rohatgi, M.D.
Cardiovascular Director of Academic Development
- Internal Medicine - Cardiology
- Diabetes & Heart Disease
- Preventive Cardiology
Anand Rohatgi, M.D., M.S.C.S., F.A.C.C., F.A.H.A., is an Associate Professor of Medicine in the Department of Internal Medicine’s Division of Cardiology at UT Southwestern Medical Center. He specializes in preventive cardiology.
Dr. Rohatgi earned his medical degree at the Duke University School of Medicine before completing an internal medicine residency at the University of Pennsylvania Health System and a cardiology fellowship at UT Southwestern. He also holds a master’s degree in clinical science from UT Southwestern’s Department of Clinical Sciences. He joined the UT Southwestern faculty in 2008.
In addition to his clinical roles, Dr. Rohatgi serves as Director of both echocardiography course education and internal medicine’s cardiology didactic curriculum. He is also a member of Internal Medicine’s Committee to Evaluate Clinical Competence. He is an active CME speaker and has given several invited national talks.
Dr. Rohatgi’s research focuses on the role of novel biomarkers in improving risk prediction for atherosclerosis and coronary artery disease. Specifically, his main area of interest is the role of high-density lipoproteins (HDL) in cardiovascular disease.
He is currently the principal investigator of “Moving Beyond HDL Cholesterol: HDL Function as a Coronary Disease Biomarker,” a five-year study funded by the National Institute of Health (NIH) career development award (K08), the American Heart Association Scientist Development Grant, and the Merck Investigator Studies Program, as well as the lead site investigator of the Eli Lilly-sponsored ACCELERATE study to evaluate the drug evacetrapib in patients with high cardiovascular risk.
Dr. Rohatgi is American Board of Internal Medicine-certified in cardiovascular disease and internal medicine. He serves as a reviewer for a number of publications, including The Lancet, Journal of the American Medical Association, Journal of the American Heart Association, American Journal of Cardiology, and Arteriosclerosis, Thrombosis, and Vascular Biology. He is an Associate Editor of the American College of Cardiology Cardiosource Biomarker Community.
A Fellow of both the American College of Cardiology and the American Heart Association, Dr. Rohatgi is a member of professional organizations that include the American College of Physicians and the National Lipid Association. He also chairs the board of directors of the nonprofit Texas Loves Children.
Meet Dr. Rohatgi
“My role is to be a guide and a teacher – to empower people to approach heart health with a holistic perspective using lifestyle and evidence-based therapies to prevent heart disease,” says UT Southwestern Medical Center cardiologist Anand Rohatgi, M.D., M.S.C.S., F.A.C.C., F.A.H.A.
A specialist in preventive cardiology, Dr. Rohatgi has expertise in treating patients with lipid/cholesterol disorders, high blood pressure, premature coronary artery disease (CAD), and a family history of CAD.
“I love developing relationships with my patients, and I get a lot of satisfaction from explaining their heart health so they understand it and know the importance of making lifestyle changes for lowering risk,” Dr. Rohatgi says.
Dr. Rohatgi considers many factors when evaluating patients’ cardiovascular risk, including their weight, cholesterol and sugar levels, blood pressure, and family history. He guides patient care with specialized tests like calcium scans and stress tests.
“Our approach allows us to develop a thorough risk assessment of patients and give them personalized plans for improving their risk,” Dr. Rohatgi says. And because patients can get all necessary services at UT Southwestern, he can ensure a continuity of care that other practices may lack.
Dr. Rohatgi also sees patients struggling with obesity and those with abnormal results from tests such as the coronary calcium (CAC) scan, advanced lipoprotein testing, and carotid intima media thickness (CIMT) test.
“Helping patients move toward optimal heart health is really about informing them and leading them to those ‘a-ha!’ moments, when they understand how it all interconnects, and then being there to guide them along,” he says.
His research interests include heart-disease risk prediction, high-density lipoproteins (HDL, or “good cholesterol”), inflammation, and atherosclerosis. He also teaches cardiology trainees, internal medicine residents, and medical students.
- Texas Medical Association
- National Lipid Association
- Dallas County Medical Society
- American Heart Association
- American College of Cardiology
- Outstanding Resident Teaching Award 2005
- Finalist - Cardiovascular Young Investigator?s Forum 2008, Northwestern University
- Council on Arteriosclerosis, Thrombosis, and Vascular Biology Travel Award for Young Investigators 2008
- Young Investigator Award 2010, American Association of Cardiologists of Indian Origin
Differential Associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule
Rohatgi A, Owens AW, Khera A, Ayers CR, Banks K, Das SR, Berry JD, McGuire DK, de Lemos JA Arteriosclerosis 2009 10 1684-90
HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events.
Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW The New England journal of medicine 2014 Nov
Resistin is an inflammatory marker of atherosclerosis in humans
Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ Circulation 2005 111(7) 932-9
HDL Cholesterol: physiology, pathophysiology, and management
Link JJ, Rohatgi A, de Lemos JA Current Problems in Cardiology 2007 32 268-314
Plasma cytokines, metabolic syndrome, and atherosclerosis in humans
Reilly MP, Rohatgi A (co-first author), McMahon K, Wolfe ML, Pinto SC, Rhodes T, Girman C, Rader DJ J Investig Med 2007 55(1) 26-35
Assessing clinical utility of carotid intima-media thickness on the basis of reclassification
Anand Rohatgi, Jarett D. Berry Journal of the American College of Cardiology Fall 2010 56(13) 1068-1069
Separating the Contenders from the Pretenders. Competitive High-throughput biomarker screening in large population-based studies.
James A. de Lemos, Anand Rohatgi Circulation Summer 2010 121(22) 2381-2383
Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population
James A. de Lemos, Mark H. Drazner, Tom Omland, Colby R. Ayers, Amit Khera, Anand Rohatgi, I. Hashim, Jarett D. Berry, Sandeep R. Das, David A. Morrow, Darren K. McGuire Journal of the American Medical Association Winter 2010 304(22) 2503-2512
HDL and Reverse Cholesterol Transport Biomarkers.
Riggs KA, Rohatgi A, Methodist DeBakey cardiovascular journal 2019 Jan-Mar 15 1 39-46
JCL roundtable: High-density lipoprotein function and reverse cholesterol transport.
Cuchel M, Rohatgi A, Sacks FM, Guyton JR, Journal of clinical lipidology 2018 Sep - Oct 12 5 1086-1094
Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease.
Abdullah SM, Defina LF, Leonard D, Barlow CE, Radford NB, Willis BL, Rohatgi A, McGuire DK, de Lemos JA, Grundy SM, Berry JD, Khera A Circulation 2018 Nov 138 21 2315-2325
Effects of Increasing Exercise Intensity and Dose on Multiple Measures of HDL (High-Density Lipoprotein) Function.
Sarzynski MA, Ruiz-Ramie JJ, Barber JL, Slentz CA, Apolzan JW, McGarrah RW, Harris MN, Church TS, Borja MS, He Y, Oda MN, Martin CK, Kraus WE, Rohatgi A Arteriosclerosis, thrombosis, and vascular biology 2018 Feb
Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study.
Khine HW, Teiber JF, Haley RW, Khera A, Ayers CR, Rohatgi A Atherosclerosis 2017 Jun 263 156-162
Sex-Based Differences in Cardiometabolic Biomarkers.
Lew J, Sanghavi M, Ayers CR, McGuire DK, Omland T, Atzler D, Gore MO, Neeland I, Berry JD, Khera A, Rohatgi A, de Lemos JA Circulation 2017 Feb 135 6 544-555
Relation of Black Race Between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (from the Dallas Heart Study).
Chandra A, Neeland IJ, Das SR, Khera A, Turer AT, Ayers CR, McGuire DK, Rohatgi A The American journal of cardiology 2015 Jan
Beyond Coronary Calcification, Family History, and C-Reactive Protein: Cholesterol Efflux Capacity and Cardiovascular Risk Prediction.
Mody P, Joshi PH, Khera A, Ayers CR, Rohatgi A Journal of the American College of Cardiology 2016 May 67 21 2480-7
High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.
Rohatgi A, Progress in cardiovascular diseases 2015 Jul-Aug 58 1 32-40
Modulating cholesterol efflux capacity to improve cardiovascular disease.
Brownell N, Rohatgi A, Current opinion in lipidology 2016 08 27 4 398-407
Reverse Cholesterol Transport and Atherosclerosis.
Rohatgi A, Arteriosclerosis, thrombosis, and vascular biology 2019 Jan 39 1 2-4
Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk.
Singh K, Rohatgi A, Journal of thoracic disease 2018 Jan 10 1 109-112
Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events.
Chindhy S, Joshi P, Khera A, Ayers CR, Hedayati SS, Rohatgi A Journal of the American College of Cardiology 2018 Aug 72 6 698-700
Is RCT (Reverse Cholesterol Transport) Ready for an RCT (Randomized Controlled Trial)?
Nambi V, Rohatgi A, Bhatt DL Journal of the American College of Cardiology 2018 Dec 72 25 3270-3273
Cholesterol Efflux Capacity as a Therapeutic Target: Rationale and Clinical Implications.
Rohatgi A, Grundy SM Journal of the American College of Cardiology 2015 Nov 66 20 2211-3
HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.
Bhatt A, Rohatgi A, Current atherosclerosis reports 2016 Jan 18 1 2
The association between HDL particle concentration and incident metabolic syndrome in the multi-ethnic Dallas Heart Study.
Mani P, Ren HY, Neeland IJ, McGuire DK, Ayers CR, Khera A, Rohatgi A Diabetes & metabolic syndrome 2016 Dec
- Differential Associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule
- Inflammation and Atherosclerosis
- High-density Lipoprotein
- Biomarkers for Atherosclerosis and Coronary Artery Disease
- Diabetes & Heart Disease
- Preventive Cardiology